AnaptysBio, Inc. (ANAB)Healthcare | Biotechnology | San Diego, United States | NasdaqGS
56.28 USD
-1.01
(-1.763%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 56.28 |
Hot Take ↕ | Aug. 22, 2026, 4:21 a.m. EDT
The long-term investment case is severely compromised by a deteriorating business trajectory. Despite a recent price recovery, the company has suffered five consecutive years of negative annual returns, with the most recent year seeing a sharp decline. This multi-year decline signals that the market has fundamentally reassessed the quality of the business, rendering the current low valuation a reflection of poor prospects rather than a margin of safety. The balance sheet is fragile, with debt nearly matching cash reserves and operating margins deeply negative, while revenue growth has turned negative. While the short-term chart shows some resilience and institutional buying, the underlying fundamentals are broken. There is no dividend to provide income, and the statistical forecast offers no directional clarity. Investors should view this as a speculative turnaround play at best, but the data currently supports a strong 'avoid' stance due to the structural decline in earnings and revenue. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.067407 |
| MSTL | 0.067417 |
| AutoTheta | 0.067549 |
| AutoARIMA | 0.070206 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 40% |
| H-stat | 0.07 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.267 |
| Excess Kurtosis | -0.74 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 2175.845 |
| Revenue per Share | 8.22 |
| Market Cap | 1,666,365,184 |
| Forward P/E | 12.92 |
| Beta | 0.40 |
| Profit Margins | -11.53% |
| Website | https://www.anaptysbio.com |
As of Aug. 22, 2026, 4:21 a.m. EDT: Speculators are positioning for a volatile range-bound scenario rather than a directional breakout. Call open interest is heavily skewed toward out-of-the-money strikes (65 and 75), suggesting bets on a rally to $75+, while put open interest concentrates deep in-the-money (35-50), indicating a hedge against a drop to $40-$50. The massive volume in September puts (all OTM) suggests a specific fear of a mid-month decline, yet the lack of significant ITM put positioning implies the market does not expect a catastrophic collapse below current levels. Implied volatility is elevated for near-term expiration, pricing in uncertainty.
| Attribute | Value |
|---|---|
| 52 Week Change | 3.2270045 |
| Address1 | 10,770 Wateridge Circle |
| Address2 | Suite 210 |
| All Time High | 89.333336 |
| All Time Low | 6.666667 |
| Ask | 72.0 |
| Ask Size | 2 |
| Audit Risk | 5 |
| Average Analyst Rating | 1.3 - Strong Buy |
| Average Daily Volume10 Day | 352,620 |
| Average Daily Volume3 Month | 599,939 |
| Average Volume | 599,939 |
| Average Volume10Days | 352,620 |
| Beta | 0.403 |
| Bid | 45.0 |
| Bid Size | 20 |
| Board Risk | 6 |
| Book Value | 0.439 |
| City | San Diego |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 56.28 |
| Current Ratio | 7.58 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 57.24 |
| Day Low | 55.375 |
| Debt To Equity | 2,175.845 |
| Display Name | AnaptysBio |
| Earnings Timestamp End | 1,788,206,400 |
| Earnings Timestamp Start | 1,788,206,400 |
| Ebitda | 41,341,000 |
| Ebitda Margins | 0.17790002 |
| Enterprise To Ebitda | 40.108 |
| Enterprise To Revenue | 7.135 |
| Enterprise Value | 1,658,090,624 |
| Eps Current Year | -0.46726 |
| Eps Forward | 4.35454 |
| Eps Trailing Twelve Months | -1.02 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 58.4401 |
| Fifty Day Average Change | -2.1601028 |
| Fifty Day Average Change Percent | -0.03696268 |
| Fifty Two Week Change Percent | 322.70044 |
| Fifty Two Week High | 72.36 |
| Fifty Two Week High Change | -16.080002 |
| Fifty Two Week High Change Percent | -0.22222224 |
| Fifty Two Week Low | 11.404 |
| Fifty Two Week Low Change | 44.876 |
| Fifty Two Week Low Change Percent | 3.9351103 |
| Fifty Two Week Range | 11.404 - 72.36 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,485,441,000,000 |
| Float Shares | 19,790,068 |
| Forward Eps | 4.35454 |
| Forward P E | 12.924442 |
| Free Cashflow | 8,323,875 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 104 |
| Fullday Change | -1.01 |
| Fullday Change Percent | -1.76296 |
| Fullday Price | 56.28 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 0.44584 |
| Gross Profits | 103,607,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.056760002 |
| Held Percent Institutions | 1.06062 |
| Implied Shares Outstanding | 29,608,481 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,776,643,200 |
| Last Split Factor | 15:10 |
| Long Business Summary | AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. The company's products include Rosnilimab, a selective pathogenic T cell deplete which completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis; ANB033, a CD122 antagonist, which is in a Phase 1b trial for celiac disease and eosinophilic esophagitis; ANB101, a BDCA2 modulator antibody which is in Phase 1a trial that specifically targets plasmacytoid dendritic cells and inhibits interferon secretion and modulates antigen presentation; dostarlimab, a PD-1 antagonist for various solid tumor indications; and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. It focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has collaborations agreement with GSK and Vanda. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California. |
| Long Name | AnaptysBio, Inc. |
| Market | us_market |
| Market Cap | 1,666,365,184 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_28462113 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -26,787,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,699,230,724 |
| Number Of Analyst Opinions | 11 |
| Open | 57.1 |
| Operating Cashflow | 4,478,000 |
| Operating Margins | -1.35534 |
| Overall Risk | 7 |
| Payout Ratio | 0.0 |
| Phone | 858 362 6295 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 56.28 |
| Post Market Time | 1,787,959,804 |
| Previous Close | 57.29 |
| Price Eps Current Year | -120.44685 |
| Price Hint | 2 |
| Price To Book | 128.20045 |
| Price To Sales Trailing12 Months | 7.170616 |
| Profit Margins | -0.11527 |
| Quick Ratio | 7.486 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.27273 |
| Region | US |
| Regular Market Change | -1.01 |
| Regular Market Change Percent | -1.76296 |
| Regular Market Day High | 57.24 |
| Regular Market Day Low | 55.375 |
| Regular Market Day Range | 55.375 - 57.24 |
| Regular Market Open | 57.1 |
| Regular Market Previous Close | 57.29 |
| Regular Market Price | 56.28 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 358,263 |
| Return On Assets | 0.06784 |
| Return On Equity | -1.14553 |
| Revenue Growth | -0.08 |
| Revenue Per Share | 8.22 |
| Sand P52 Week Change | 0.1966995 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 29,608,481 |
| Shares Percent Shares Out | 0.17959999 |
| Shares Short | 5,317,981 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 4,999,494 |
| Short Name | AnaptysBio, Inc. |
| Short Percent Of Float | 0.39970002 |
| Short Ratio | 8.47 |
| Source Interval | 15 |
| State | CA |
| Symbol | ANAB |
| Target High Price | 140.0 |
| Target Low Price | 70.0 |
| Target Mean Price | 86.63636 |
| Target Median Price | 81.0 |
| Total Cash | 286,455,008 |
| Total Cash Per Share | 9.844 |
| Total Debt | 277,355,008 |
| Total Revenue | 232,388,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.02 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 45.423218 |
| Two Hundred Day Average Change | 10.856781 |
| Two Hundred Day Average Change Percent | 0.23901391 |
| Type Disp | Equity |
| Volume | 358,263 |
| Website | https://www.anaptysbio.com |
| Zip | 92,121-5801 |